3/2
04:30 pm
trda
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
01:30 am
trda
Low
Report
2/26
07:32 am
trda
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
07:00 am
trda
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2/18
08:13 am
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/17
07:30 am
trda
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study [Yahoo! Finance]
Low
Report
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study [Yahoo! Finance]
2/17
07:00 am
trda
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Low
Report
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
2/13
06:29 am
trda
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
High
Report
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/10
06:05 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) was given a new $20.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) was given a new $20.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
2/4
08:29 am
trda
Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/4
07:00 am
trda
Entrada Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Entrada Therapeutics to Present at Upcoming Investor Conferences
1/28
08:00 am
trda
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
1/8
07:00 am
trda
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
Low
Report
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
12/17
04:34 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/17
07:00 am
trda
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
04:17 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
04:18 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/4
04:30 pm
trda
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)